テルイ ヤスヒト
TERUI Yasuhito
照井 康仁 所属 埼玉医科大学 医学部 血液内科 職種 教授 |
|
論文種別 | 学術雑誌(原著) |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma |
掲載誌名 | 正式名:Cancer Sci ISSNコード:13497006 |
掲載区分 | 国外 |
巻・号・頁 | 112,2426-2435頁 |
著者・共著者 | Kawai, H., Ando, K., Maruyama, D., Yamamoto, K., Kiyohara, E., Terui, Y., Fukuhara, N., Miyagaki, T., Tokura, Y., Sakata-Yanagimoto, M., Igarashi, T., Kuroda, J., Fujita, J., Uchida, T., Ishikawa, T., Yonekura, K., Kato, K., Nakanishi, T., Nakai, K., Matsunaga, R., Tobinai, K. |
発行年月 | 2021 |
概要 | It shares an amino acid sequence with denileukin diftitox, but has improved purity and an increased percentage of active monomer. Among the 36 patients with PTCL and CTCL, objective response rate based on the independent review was 36%. The median progression-free survival was 3.1 months . The common AEs observed were increased AST/ ALT, hypoalbuminemia, lymphopenia, and pyrexia. Our results indicated that a 9 µg/kg/d dose of E7777 shows efficacy and a manageable safety profile in Japanese patients with relapsed or refractory PTCL and CTCL, with clinical activity observed across the range of CD25 expression. The common AEs were manageable, but increase in ALT / AST, hypoalbuminemia, and capillary leak syndrome should be carefully managed during the treatment. |
DOI | 10.1111/cas.14906 |
文献番号 | 33792128 |